Study summary
Ivonescimab beat pembrolizumab in lung cancer
27% lowerrisk of death vs pembrolizumab
What was tested
Ivonescimab, one antibody that blocks both PD-1 and VEGF, against pembrolizumab as first treatment for PD-L1 positive lung cancer. This was not an esophageal cancer trial.
What they found
- Typical survival was 30.8 months with ivonescimab and 22.6 months with pembrolizumab (hazard ratio 0.73).
- Time before the cancer grew was 11.1 vs 5.8 months.
What it means
The first drug to beat pembrolizumab head to head. Five small trials are now testing it in squamous esophageal cancer; none has reported.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.